Do you know your asset's rare disease launch archetype? A rare disease is designated by having less than 200,000 patients in the US. However, when we consider rare diseases as a category, we start to form a different understanding of the scale; they affect 30 million...
Overcoming Launch Challenges and Maximizing Success in a Complex Landscape In the pharmaceutical industry, appropriately allocating resources and planning for a drug launch has never been more crucial. There are new obstacles and challenges with supply chain management and the application of multi-tier pricing. Moreover, as...
Executive Order 14091: Pivotal Opportunity for Healthcare Manufacturers  Understanding the Impact and Strategies for Manufacturers to Address SDoH On February 16, 2023, President Biden signed Executive Order 14091, titled 'Advancing Health Equity and Racial Justice by Addressing the Social Determinants of Health.' This Order has immediate and significant...
Interview with Pharmaceutical Executive Our Partner, Brian Torres, sat down with Pharmaceutical Executive to discuss trends in patient support services, how those trends affect a broader commercialization strategy, and how digital health fits into a product launch. To learn more about our Patient Services Strategy and Design...
Components of a pharma and biotech go-to-market strategy After many years of drug development and getting ready for product launch you are finally at the tactical planning stage. Getting to this phase is a major accomplishment, but this does not guarantee commercial prosperity without the structure...
Components of a pharma and biotech go-to-market strategy Completing the drug development process and getting FDA approval to go-to-market with a new drug is a major accomplishment in itself, but this does not guarantee the commercial prosperity of the new product. To assure launch success, rapid...
Components of a pharma and biotech go-to-market strategy Getting product launches right is more critical than ever before. The Food and Drug Administration (FDA) approved 50 new drug therapies for 2021 and the accelerated pace looks to continue for 2022. Pharma companies navigating the launch of...
Components of a pharma and biotech go-to-market strategy Getting FDA approval for a product is only one part of the battle for pharma and biotech companies. There are many next steps for drugmakers to consider in order to navigate the launch of a new drug or...
How the BBBA intends to lower drug costs The Build Back Better Act (BBBA) drug pricing framework is being closely followed by the industry. The Build Back Better Act narrowly passed through the house on November 19th and currently sits with the Senate. All the proposed...
Covid Pharma and Biotech Drug Launch Strategies Become the New Normal The Covid-19 pandemic has impacted pharma and biotech companies, both small and large, forcing them to shift their approach to drug launch strategies. Across the industry, companies that received approval and launched products either shortly...
